Clasado Biosciences Establishes Scientific Advisory Board
Clasado Biosciences (U.K.), developer of the proprietary prebiotic ingredient Bimuno GOS, is collaborating
(L-R) Prof. Matthias Floor, Prof. Georg Holländer, Per Rehné, Prof. Huub Savelkoul, Dr. Lucien Harthoorn, Dr. Frederic Narbel
with esteemed scientists through a newly established scientific advisory board to further develop the future role of prebiotics within medical nutrition.
According to the company, this strategic initiative highlights Clasado’s commitment to driving scientific advancements in the health and nutrition industry through microbiome modulation. Notably, this represents a step forward in the exploration and utilization of prebiotics as part of dietary health interventions.
The collaboration consists of Clasado members Per Rehné (CEO), Dr. Frederic Narbel (Vice President of Sales B2B), Dr. Lucien Harthoorn (R&D Director), and renowned scientific advisors:
- Professor Georg Holländer: Professor and head of the Department of Pediatrics at the University of Oxford (U.K.), and director of the Botnar Research Centre for Child Health (Basel, Switzerland). He is an expert in immunology with a keen interest in thymus and T cell biology and has authored more than 100 publications in peer-reviewed journals.
- Professor Matthias Kloor: Deputy medical director at the Department of Applied Tumor Biology of the Institute of Pathology at Heidelberg University Hospital (Germany), and author of more than 190 publications in peer-reviewed scientific journals. He has also received several scientific honors.
- Professor Huub Savelkoul: After being professor of cell biology and immunology from 2000 to 2022 at Wageningen University and Research (The Netherlands) he retired in 2023, and has published almost 400 peer-reviewed research papers. He has received several awards for his research and contribution to education.
Clasado said that the company is proud to be working with these experts to sharpen the scientific agenda and share valuable insights and experiences to propel the future of prebiotic development and use in medical nutrition and beyond.
“The future of prebiotics, specifically galactooligosaccharides (GOS) and potential novel oligosaccharides holds immense promise in the medical nutrition field—and we are working on uncovering the potential,” said Harthoorn. “Clasado’s strategic involvement in this area showcases our commitment to driving prebiotic capabilities forward, and we are honored to work alongside such esteemed scientific advisors to achieve our shared goals.”
The scientific advisory board follows a submission involving Clasado, which enabled GOS to be permitted by the European Commission for use in foods for special medical purposes (FSMPs), further driving the future potential of prebiotics in health and medical applications.
“As we look to the future of medical nutrition, gut microbiome modulation holds great potential and could play a key role in improving human health,” Rehné noted. “Driven by rising global awareness, eyes are on the capabilities of prebiotics, which makes initiatives such as the new scientific advisory board all the more important. For us, this represents an opportunity to better understand where prebiotics can fit into health care strategies. Through the power of science and collaboration, we’re aiming to expand the event horizon of the prebiotic category and how it could change areas of application.
“Through our continued research and discussion, we are painting a clearer picture of where prebiotics can support in the day to day management of health, such as gastrointestinal, immune and cognitive health, and we’re excited to be exploring the synergies beyond.”
For more information, visit https://clasado.com.
